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Background: Human milk contains immune molecules involved in the protection of newborns against infections.
We analyzed the concentration of Deleted in Malignant Brain Tumors 1 (DMBT1), a protein with functions in innate
immunity, in breast milk.
Methods: DMBT1 was detected in breast milk by Western blotting and its concentration was quantified by ELISA in
95 breast milk samples collected from mothers of preterm and term neonates during the first four weeks after
delivery. Possible effects of maternal or neonatal parameters were analyzed by different statistical tests.
Results: The mean DMBT1 concentration (± standard error of the mean) in the tested milk samples was
2.48 ± 0.26 μg/mL (range: 0.112 μg/mL to 17.984 μg/mL) and represented 0.0087% of the total protein content. The
comparison between the newborns with infection and the newborns without infection revealed significantly higher
DMBT1 concentrations in breast milk in the group with infection (6.72 ± 2.53 μg/mL versus 2.20 ± 0.35 μg/mL
(P= 0.031)). Neither maternal nor neonatal parameters showed a correlation with the milk DMBT1 levels.
Conclusions: DMBT1 is a component of breast milk after birth and is up-regulated in the breast milk from mothers
with newborns suffering from neonatal infection. Thus, breast milk DMBT1 may be part of the innate immunity
similar to secretory IgA.
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The glycoprotein Deleted in Malignant Brain Tumors 1
(DMBT1), also known as glycoprotein 340 (gp-340) or
as salivary agglutinin, is a member of the scavenger re-
ceptor cysteine-rich (SRCR) proteins with functions in
innate immunity and epithelial differentiation [1,2]. Up-
regulation of DMBT1 was observed in different tissues
with inflammation [3-5]. The protein DMBT1 interacts
with various defense factors such as, e.g., surfactant pro-
tein A and D and secretory IgA [1]. DMBT1 is able to
directly bind to and aggregate various bacteria, which is
sufficient to substantially suppress bacterial infection
in vitro [6]. The broad bacterial-binding specificity is at
least in part based on DMBT1 functioning as a pattern* Correspondence: Hanna.Mueller@med.uni-heidelberg.de
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distribution, and reproduction in any mediumrecognition molecule for poly-sulfated and poly-
phosphorylated ligands [7].
In newborns, innate immunity is of particular import-
ance, because the function of the adaptive immune sys-
tem is not yet well established at these early time points
of life. Especially premature infants benefit from the in-
nate immunity because the delivery of IgG from the
mother through the placenta to the fetus approximately
begins in the second trimester, which is interrupted by
the premature birth. On the other hand, neonatal infec-
tion and sepsis contribute largely to morbidity and le-
thality during early life [8-11].
The DMBT1 gene has further been suggested as a
tumor suppressor gene for different cancer types [12].
Several studies reported a reduced DMBT1 expression
in breast cancer and a variable expression in normal
breast tissue [13-15]. Strong expression upon inflamma-
tion was seen in some cases [15]. Possibly, DMBT1entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 The distribution of the gestational age (A) and weight
(B) at birth of the included infants.
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of SRCR domains and/or promoter activity contribute to
these patterns [16,17]. However, in mammary gland tis-
sues, DMBT1 is expressed in the epithelium of the
mammary ducts and glands, which are also responsible
for breast milk production. Breast milk is known to con-
tain different proteins with functions in innate immunity
such as lactoferrin and secretory IgA with beneficial
functions in newborns [18-20]. We therefore hypothe-
sized that breast milk may contain DMBT1 and that
DMBT1 levels in breast milk could potentially correlate
with infections in the neonates. To test this hypothesis
we examined the DMBT1 concentrations in breast milk
from mothers after delivery and tested whether the
DMBT1 concentrations correlated with maternal and
neonatal parameters.
Methods
Patients and samples
The study was performed with approval of the responsible
Ethics Committee of the University of Heidelberg,
Germany, and in compliance with the Helsinki Declaration.
The parents agreed by informed consent. Thirty mothers
who delivered at the Perinatal Center of the University
Hospital Center of Heidelberg were studied prospectively.
The clinical data of these mothers are demonstrated in
Table 1. Four mothers had twins, in these cases we included
only the first born infant in the study. The included new-
borns comprised 14 females and 16 males. Gestational age
was defined as time elapsed between the first day of the
last menstrual period and the day of delivery. The
included infants had an average gestational age of
34.5± 0.62 weeks (mean ± SEM; range: 26 – 40 weeks)
(Figure 1A). The averaged weight at birth was
2225± 136.6 g (mean ± SEM; range: 590 – 3600 g)
(Figure 1B). A sample of 1 mL fresh milk obtained by a
breast milk pump was taken for determination of theTable 1 Characteristics of the mothers
Parameter
Maternal age (years; mean and range) 30.2 (21-39)
Number of pregnancies (mean and range) 2 (1-6)
Parity number (mean and range) 1.5 (1-6)
Mothers with abortion(s) (n) 10
Mothers with pre-eclampsia (n) 1
Mothers with HELLP syndrome (n) 3
Antiphospholipid antibody syndrome (n) 1
Maternal infection (n) 9
Antenatal steroids (yes/no) 13/17
Rupture of membranes (in hours prior delivery,
mean and range)
2.9 (0-22)
Mode of delivery (vaginal delivery/cesarean section) 7/23DMBT1 levels once a week in the first four weeks, begin-
ning on day 4 after delivery. All samples were left
unpooled and stored immediately at -20°C until the ana-
lyses were performed. From 19 mothers all 4 samples were
collected, while from 3 mothers only 3 samples, from 2
mothers two samples and from the remaining 6 mothers
only one sample was obtained. This gave rise to a total of
95 samples, which were examined.
The DMBT1 concentrations of the breast milk mea-
sured for each mother were tested for correlation with
clinical data and diseases of the newborns. The analysis
included gestational age (weeks), birth weight (g), pre-
mature rupture of the membranes, increased C-reactive
protein of the mother, maternal leukocytosis, prenatal
group B Streptococci colonization of the mother, neo-
natal infection (C-reactive protein >10 mg/L, clinical
signs of infection and consecutive therapy with antibio-
tics), respiratory distress syndrome, surfactant applica-
tion, mechanical ventilation, therapy with continuous
positive airway pressure (CPAP), and the presence/ab-
sence of persistent ductus arteriosus.
Sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) and western blot analysis
Separation of breast milk proteins was performed under
non-reducing conditions on 8% polyacrylamide gels. The
Figure 2 Western blotting of breast milk from one exemplary
individual included in the study. Different antibodies against
DMBT1 (Hyb213-06 or Anti-DMBT1p84) were used. The samples of
week 1, 2, 3 and 4 after delivery (indicated with the numbers 1-4)
were tested.
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branes (Whatman, GE Healthcare, Munich, Germany).
The membranes were then incubated with the DMBT1-
specific monoclonal antibody Hyb213-06 (Antibodyshop,
Dianova, Hamburg, Germany) or the polyclonal anti-serum
anti-DMBT1p84 [3]. After washing with Tris-buffered
saline containing 0.1% Tween 20 (Gerbu, Gaiberg,
Germany) (TBS-T) the membranes were incubated with
the respective secondary antibodies (SC-2005, goat
anti-mouse IgG, or SC-2004, goat anti-rabbit IgG, both
conjugated with horseradish peroxidase, Santa Cruz
Biotechnology, Munich, Germany).
Analysis of the DMBT1 concentration in breast milk by
enzyme-linked immunosorbent assay (ELISA)
Microtiter plates (Microcolon, Greiner Bio-One GmbH,
Essen, Germany) were coated with breast milk over
night at 4°C. Purified human recombinant DMBT1
(hrDMBT1) [21] was used as concentration standard.
The plates were washed with TBS-T and incubated with
the DMBT1-specific antibody Hyb213-06 (Antibody-
shop, Dianova, Hamburg, Germany) followed by an in-
cubation step with the secondary antibody AP 300P
(sheep anti-mouse IgG, horseradish peroxidase-conju-
gated, Chemicon International, Temecula, California,
USA). The bound enzyme was determined by adminis-
trating TMB-substrate solution [125 μg/mL 3,30,5,50-tet-
ramethyl-benzidine; 125 μg/mL in 0.1 M citrate buffer
pH 4.5 with 0.05% (v/v) H2O2]. After 20 minutes the re-
action was stopped by 2 M HCl and the intensity of the
dye reaction was analyzed at 450 nm in an ELISA reader
(Multiscan Ascent, ELISA Reader, Thermo Fisher Scientific
Inc., Rockford, Illinois, USA).
Determination of the total protein content
The total protein content of the breast milk samples
were analyzed with the Lowry protein assay as described
by Polberger and Lönnerdal [22].
Statistics
The statistical analysis was performed with the SAS soft-
ware package, release 9.2 (SAS Inc., Cary, NC, USA).
We calculated means and standard errors of the mean
(SEM) for quantitative parameters. To analyze poten-
tially time-dependent changes of the DMBT1 concentra-
tions und to search for parameters influencing the
DMBT1 concentrations we used a variance analysis for
repeated measurements using the SAS procedure PROC
MIXED as this procedure is very efficient in the case of
missing values. For analysis of the time-dependent
changes of the total protein content a linear regression
analysis was performed (where the number of weeks
was regarded as a quantitative variable). To test the
correlation between two quantitative parameters, wecalculated the Pearson’s correlation coefficient. A logistic
regression was used to determine the influence of one or
several parameters on a binary outcome (for examples
the outcome “infection” with the values “yes” and “no”).
To compare two samples sets we performed the Mann–
Whitney U test (quantitative, non-normally distributed
data). Test results with P-values less than 0.05 were
regarded as statistically significant.
Results
Detection of DMBT1 in breast milk
To test whether breast milk contains DMBT1, we per-
formed Western blotting using different antibodies
against DMBT1. DMBT1-specific bands with the
expected size of approximately 340 kDa were readily
detected by both antibodies (Figure 2). The observed
double bands could be due to different glycosylation
and/or different alleles of the DMBT1 gene [16].
Determination of the DMBT1 concentration in breast milk
by enzyme-linked immunosorbent assay (ELISA)
We used the enzyme-linked immunosorbent assay to
quantify the DMBT1-content in the entire panel of
breast milk samples. Figure 3 displays the DMBT1
Figure 3 DMBT1 concentrations of all 95 breast milk samples. The samples were analyzed by ELISA using the monoclonal antibody
Hyb213-06.
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nantly expressed DMBT1 of known concentration as the
standard. The mean DMBT1 concentration in the breast
milk samples was 2.48 ± 0.26 μg/mL (mean ± SEM) with
a lowest DMBT1 concentration of 0.112 μg/mL and a
highest of 17.984 μg/mL.DMBT1 concentrations in dependence of age (weeks after
birth)
One sample per week 1-4 after delivery was analyzed, but
there was no significant association between age (weeks
after delivery) and DMBT1 concentration in the breast
milk (P= 0.456; variance analysis for repeated measure-
ments). The mean DMBT1 concentrations in the week
1-4 after birth are displayed in Table 2 and Figure 4. Nu-
merically, the DMBT1 concentrations decreased after
week 1 and 2 and reached a baseline in week 3 and 4.
However, because the time-dependent decrease was
not statistically significant, we used the mean values of
the samples obtained from each individual mother for
testing the association of the DMBT1 concentration with
different parameters.DMBT1 content in milk relative to the total protein
content
The mean total protein content of all included samples
decreased linearly in an age-dependent manner
(Figure 5A). Therefore, we used a linear regression ana-
lysis and found that total protein content decreased by
about 0.366 g/100 mL on average per week (P < 0.0001).Table 2 DMBT1 concentrations of breast milk in
dependence of the time after delivery
Week after birth Week 1 Week 2 Week 3 Week 4
mean DMBT1-conc.
(μg/mL)
3.21 2.47 1.99 2.01
SEM 0.74 0.43 0.19 0.4
N 28 24 23 20
Conc. concentration.The mean percentage of DMBT1 from the total pro-
tein content was 0.0087% (range: 0.0003 to 0.105%) and
no significant changes during the first four weeks of age
were observed (mean percentage; Figure 5B): week 1:
0.0116%; week 2: 0.0082%; week 3: 0.0072%; week 4:
0.0066% (P= 0.5244).DMBT1 concentration and gestational age at birth
The correlation analysis showed no significant associ-
ation between the gestational age at birth and the
DMBT1 concentration of breast milk (P= 0.479). The
same applied, when using the mean value of the
analyzed samples of each infant in week 1-4 (P= 0.520,
r = -0.122, Pearson’s correlation).DMBT1 concentration and birth weight
The statistical tests did not identify a significant associ-
ation between birth weight and DMBT1 concentration
of the breast milk (P= 0.438; regression analysis and
P= 0.223, r = -0.229; Pearson’s correlation with mean
values of all samples of each infant).Figure 4 DMBT1 concentrations (mean ± SEM) within the
breast milk in the first four weeks of life. Data included all 95
samples.
Figure 5 DMBT1 and total protein content. The total protein
concentration (mean ± SEM) decreased in the first four weeks after
birth (A). B illustrated the percentage of DMBT1 from the total
protein content (mean ± SEM) in the first four weeks of life.
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DMBT1 plays an important role in innate immunity
[5,6,23]. Therefore, we tested the association between
DMBT1 concentration in breast milk and neonatal infec-
tion. Six of the 30 (20%) included infants with 13 samples
of breast milk had a neonatal infection (C-reactive protein
>10 mg/L, clinical signs of infection and consecutive
therapy with antibiotics). All neonatal infections manifested
within the first seven days of life. Staphylococcus aureus,
Staphylococcus haemolyticus and group B Streptotococci
were observed in the cultures of blood and of the smears
from the ears or the umbilicus. The statistical analysis using
logistic regression and the mean values of all samples of
each infant revealed a significant correlation between the
DMBT1 concentrations in breast milk and the occurrence
of neonatal infections (P=0.044). The comparison between
the newborns with infection and the newborns without
infection revealed significantly higher DMBT1 concentra-
tions within the breast milk of the group with infection
(6.72±2.53 μg/mL versus 2.20 ± 0.35 μg/mL (mean ± SEM;P= 0.031, Mann–Whitney U-test; Figure 6A)). The
lowest mean DMBT1 concentrations in breast milk from
mothers, which had infants with neonatal infections,
was 1.838 μg/mL and the highest concentration was
17.984 μg/mL.
Here we provide a mathematical equation derived
from a logistic regression to assess the probability of the
newborn to have an infection for a distinct DMBT1 con-
centration in the breast milk.
In this case the DMBT1 concentration in the breast
milk would be considered as a predictive marker for a
neonatal infection:
P ¼ exp 2:7898þ 0:3968  DMBT1 concð Þ
1þ exp 2:7898þ 0:3968  DMBT1 concð Þ
where P is the probability for a neonatal infection of the
newborn and DMBT1 conc is the mean value of all mea-
sured DMBT1 concentrations in breast milk of each
mother in the first four weeks of life. Using this formula,
a P-value between 0 (0%) and 1 (100%) is guaranteed.
The positive regression parameter b = 0.3968 indicates
that the probability for the infection increases with
higher DMBT1-values.
To test the predictive character of this formula we
used the DMBT1 concentration in the respective
mother’s breast milk to calculate the probability of neo-
natal infection for the infants of our study with versus
without confirmed infections (Figure 6B). For the infants
with confirmed infections we calculated a probability of
42.2% (mean; range: 11.3 – 98.7%) and for the infants
without infection of 14.5% (mean; range: 7.4 – 69.7%).
Because the lowest mean DMBT1 breast milk concentra-
tion associated with an infected infant is 1.838 μg/mL, we
assume that above this value the sensitivity for predicting a
neonatal infection is 100%, but this would be accompanied
by many false-positive predictions.
DMBT1 concentration and other clinical parameters
The association between the DMBT1 breast milk con-
centration and different maternal parameters was evalu-
ated with a logistic regression and the results are
summarized in Table 3. Maternal infection or bacterial
colonization and premature rupture of the membranes
had no influence on the DMBT1 concentration. In
addition, also the other neonatal parameters that were
tested were without any significant association with the
mean DMBT1 concentration (Table 3).
Discussion
Breast milk consists of proteins, carbohydrates – espe-
cially lactose -, fat (97% triglycerides), vitamins, minerals,
and viable cells, for example, leukocytes and macro-
phages [18-20]. The protein fraction comprises multiple
Figure 6 DMBT1 concentration in breast milk and neonatal infections. The DMBT1 concentration (mean ± SEM) in the breast milk from
mothers of infants with neonatal infections versus infants without neonatal infection are demonstrated in A. The breast milk from mothers of
neonates with infections showed significantly higher DMBT1 concentrations compared to the breast milk from mothers of neonates without
infections (* P <0.05). B illustrates the calculated probability for an infection using the DMBT1 concentration-based mathematical equation for
infants with versus without confirmed neonatal infection.
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ferrin, Mac-2–binding protein, secretory IgA (sIgA), but
many of these are related to defense functions. Earlier
studies pointed to variable DMBT1 expression in normal
breast tissue and a strong expression was detected in
some cases with inflammation [13-15]. According to
these studies, DMBT1 is expressed in the epithelium of
the mammary ducts and glands, i.e. to structures, which
are also responsible for the production and secretion ofTable 3 Correlation between DMBT1 concentration of the
breast milk and different maternal and neonatal
parameters
Parameter P-value Test
Maternal C-reactive protein
>5 mg/L
0.167 Logistic regression
Maternal C-reactive protein
>12 mg/L
0.313 Logistic regression
Maternal leukocytosis 0.460 Logistic regression
Premature rupture of the
membranes
0.671 Logistic regression
Maternal group B streptococcal
colonization
0.778 Logistic regression
Respiratory distress syndrome 0.100 Logistic regression
Surfactant application 0.062 Logistic regression
Mechanical ventilation 0.062 Logistic regression
Therapy with continuous positive
airway pressure (CPAP)
0.072 Logistic regression
Persistent ductus arteriosus 0.102 Logistic regressionbreast milk. We therefore considered it possible that
DMBT1 could be secreted to breast milk after delivery.
While Danielsson Niemi and co-workers could not de-
tect DMBT1 in breast milk performing Western blotting
with four different antibodies (mAb143, mAb303,
Hyb213-01, Hyb213-06) against DMBT1 [24], our data
point to the presence of DMBT1 in breast milk as con-
firmed by using two different methods (ELISA and
Western blotting) and two different antibodies (Hyb213-06,
anti-DMBT1p84). These findings strongly suggest that
DMBT1 is one of the various breast milk components with
functions in innate immunity, where it may function as a
pattern-recognition molecule for pathogens and would
co-localize with various of its known binding partners
such as sIgA or lactoferrin.
The DMBT1 concentrations in our study ranged be-
tween 0.112 μg/mL and 17.984 μg/mL. The highest
DMBT1 concentration was found in the first week after
delivery, which then declines to an apparent steady-state
level of approximately 2 μg/mL in week 3 and 4 after
birth. This resembles the dynamics of other protective
proteins such as lactoferrin, Mac-2 binding protein and
sIgA in breast milk.
Lactoferrin, an interaction partner of DMBT1, has
functions in the defense against bacterial and viral infec-
tions and was found in concentrations up to 3.3 mg/mL
[19,25,26]. Montagne et al. found the highest lactoferrin
concentrations directly after birth (5.8 mg/mL), decreasing
in the first consecutive days and then again increasing
after day 28 [25]. The Mac-2 binding protein (Mac-2 BP)
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Mac-2 BP is expressed in tissues containing cavity-lining
secretory epithelia (stomach, gut). It can function as an
immune-stimulatory and anti-infective agent. D’Ostilio
[27] detected Mac-2 BP in human breast milk and showed
an increase until days 2-3 postpartum (13.4 μg/mL to
79.2 μg/mL) followed by a decrease of the Mac-2 BP
concentration to <10 μg/mL on day 6 postpartum. They
additionally performed one measurement 4 weeks after
delivery and found concentrations of 5.3 ± 4.8 μg/mL.
The mothers and infants in this study were healthy and
had no infections. Likewise, the highest levels of
secretory IgA (sIgA) were found directly after birth
(19.0 mg/mL) and a decrease was reported throughout
the lactation period (mature milk: 1.1 mg/mL) [28].
Similarly, cytokine levels significantly decrease in mature
milk in comparison to the first milk samples postpar-
tum, but in patients with preeclampsia the high proin-
flammatory cytokine levels were persistent throughout
lactation [29]. Thus, the DMBT1 concentrations in our
study follow a similar course, but were lower than the
detected concentrations of lactoferrin, Mac-2 BP, and
sIgA. Assuming an average amount of breast milk of
120 mL per day in the first days after delivery for term
neonates, these infants receive 385 μg/day DMBT1
(3.21 μg/mL x 120 mL/day). In extreme premature
infants, the amount of breast milk in the first days of life
was about 12 x 1 mL to 12 x 3 mL per day (depending
on the gestational age of the infants) corresponding to
39 μg and 116 μg DMBT1 per day.
Interestingly, our results revealed that breast milk from
mothers with newborns suffering from neonatal infec-
tions showed higher DMBT1 concentrations in compari-
son to the breast milk from mothers with healthy
newborns. In contrast, no correlation was found between
the DMBT1 concentration in the breast milk and a ma-
ternal bacterial infection or a risk factor for chorioamnio-
nitis (premature rupture of the membranes). It is,
however, documented that sIgA levels in breast milk in-
crease in response to the maternal environment [30,31].
In this case, antigen exposure in the gut or the respira-
tory tract activates B cell trafficking to the mammary
glands, which then results in IgA secretion and trans-
location of sIgA to the breast milk [30-32]. While the
precise mechanisms behind the up-regulation of DMBT1
levels in breast milk remain to be determined, it resem-
bles the observations made for the Mac-2 BP. Fornarini
et al. showed a significant association between the Mac-2
BP concentration in breast milk and an acute respiratory
infection of the newborn in the first 12 months of life. The
infants were breast feeded for 4-5 months. Newborns with
high Mac-2 BP levels in the breast milk of their
mothers had a lower rate of respiratory infections indi-
cating a protective effect [33]. Because we analyzed onlyneonatal infections in our study group and the breast
feeding time considered in our study is substantially
shorter, it is not possible with the present data sets to
compare the effects of DMBT1 on the infections rate
as was performed in the earlier study of Mac2-BP.
Because of the blood volume using for blood culture
(0.5-1 mL) only one third of the infants with neonatal
infections showed positive blood cultures. To compensate
for possibly low sensitivity we used additional criteria for
the diagnosis infection (C-reactive protein >10 mg/L,
clinical signs of infection as fever, and/or detection of
bacteria in smears e. g. omphalitis), but we cannot rule out
that a very strong inflammation was interpreted as
neonatal infection.
According to the present data, the use of the DMBT1
concentration in the breast milk as a marker for neo-
natal infection is limited. The DMBT1 concentration in
the breast milk of newborns with neonatal infection has
a range between 1.838 and 17.984 μg/mL. This large
range and the crossover of this range with the range of
the DMBT1 concentration of healthy neonates would re-
sult in a high rate of false positive predictions. One rea-
son could be basal differences of the DMBT1 expression
levels in the breast tissues of individual women [13-15],
which may depend on variable promotor activity [17].
Thus, the DMBT1 concentration of the breast milk can
potentially contribute to diagnose a neonatal infection,
but it is not able to replace established methods such as
measurement of C-reactive protein levels to determine a
neonatal infection.
Conclusions
The results of our study demonstrate that DMBT1,
known as a protein with functions in innate immunity,
is detectable in breast milk after delivery. Higher
DMBT1 concentrations are found in the breast milk
from mothers of newborns suffering from neonatal in-
fection in comparison to those of healthy newborns sug-
gesting that breast milk DMBT1 may be part of
mechanisms to protect the newborns from infections.
Although DMBT1 has been shown to directly bind to
and aggregate bacteria and that this is sufficient to sub-
stantially suppress infection in vitro, its roles in innate
immunity in breast milk remains to be determined in
detail because part of its functions may rely on or be
influenced by specific interaction partners in milk.
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